Costs of coronary restenosis (Lovastatin Restenosis Trial).
Within the Lovastatin Restenosis Trial, restenosis has been clearly shown to increase resource utilization and costs. While it is not possible to generalize these results to other patient populations, it is clear that successful efforts to decrease restenosis will certainly improve efficacy while decreasing follow-up costs and increasing the cost-effectiveness of intervention in the coronaries.
Gilbert
S P
SP
Department of Medicine, Emory University School Medicine, Atlanta, Georgia, USA.
Weintraub
W S
WS
Talley
J D
JD
Boccuzzi
S J
SJ
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000191:economics* / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008148:Lovastatin / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011859:Radiography; D012008:Recurrence; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D008148:Lovastatin